Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheumaÂtology in the halcyon days of the 1970s and 80s. That’s not to belittle the world we now live in, with so many treatment options for our…
Ethan Craig was not pleased. As a reader of this column, you know that Dr. Craig is an assistant professor of clinical medicine in the Division of Rheumatology at the University of Pennsylvania and an associate editor of The Rheumatologist. On this particular morning, however, he was the father of a 5-year-old who woke up…
Our patient was a 33-year-old, 5’2″ Asian woman with a past medical history of systemic lupus erythematosus (SLE). The diagnosis was based on serologies positive for anti-nuclear antibodies (ANAs), as well as antibodies to Sm, RNP and SSA. Her illness included neuropsychiatric and cutaneous involvement. She also had a diagnosis of Hashimoto’s thyroiditis. She presented…
Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.
ACR practice management staff are offering a free, tailored, one-hour Lunch & Learn series to help members, practices and their staff become familiar with new office and outpatient evaluation and management codes and documentation guidelines that went into effect Jan. 1.
On Feb. 1, UnitedHealthcare enacted a new policy designating Avsola and Inflectra as the preferred infliximab products for UHC commercial plans. ACR leaders have urged UHC to allow existing patients to continue on their current medication.
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
At the helm of the Collaborative Initiatives Special Committee (COIN), Rosalind Ramsey-Goldman, MD, DrPH, will oversee projects to tackle disparities within rheumatologic care, improve the inclusiveness of ACR initiatives, advance professional development in rheumatology topics and more.
In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.